Hanmi Invests $20 Million in Allegro for Eye Disease Drug

Hanmi Pharmaceutical of South Korea will invest $20 million into California-based Allegro Ophthalmics, LLC to obtain rights to Luminate®, a vitreo-retinal treatment, in China and South Korea. Hanmi will also pay an undisclosed licensing fee. Luminate is an integrin peptide, currently in several US Phase II trials, which is aimed at several diseases that cause blindness. More details.... Stock Symbol: (KRX: 128940) Share this with colleagues: // //